FCGRT and myasthenia gravis: In addition, rozanolixizumab, another FcRn inhibitor, has demonstrated better efficacy for MuSK-MG in its Phase III study (22), indicating that FcRn is gradually becoming a powerful tool in the treatment of MuSK-MG.